Omid Hamid MD
Chief of Research and Immunotherapy • ImmunoOncology • Phase I Clinical Trials • Melanoma • Cutaneous Oncology
Last synced from Twitter 10m ago
New "Blueprint" of Exhausted T Cell Lifespan Could Help Build Better Immunotherapies
Mirage News 43h 1 tweets
E. John Wherry, PhDPHILADELPHIA – Mapping out the lifespan of the immune cells that lose steam in the body's fight against cancer is giving Penn Medicine...
Omid Hamid MD New "Blueprint" of Exhausted T Cell Lifespan Could Help Build Better Immunotherapies 43h
Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program
GlobeNewswire News Room 43h 1 tweets
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up 36.4% Overall Response Rate (ORR) Maintained SAN CARLOS, Calif., May...
Omid Hamid MD Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program Nasdaq:IOVA ⁦⁩ ⁦⁩ #melanoma 43h
Meeting Library | Meeting Library
Meetinglibrary.asco.org 49h 1 tweets
Omid Hamid MD #ASCO20 SAY WHAT !!! MCY-M11, anti-human-mesothelin CAR mRNA transfected MRNA is transfected by nonviral eleectroporation-process completed <1 day ! Multiple doses and cycles !! GIVEN INTRAPERITONEALLY !! #ovariancancer #mesothelioma 49h
Meeting Library | Meeting Library
Meetinglibrary.asco.org 50h 1 tweets
Omid Hamid MD #ASCO20 presents #MGD013, a bispecific DART molecule binding PD‑1 and LAG‑3, then moves on to triplet therapy 50h
Meeting Library | Meeting Library
Meetinglibrary.asco.org 52h 1 tweets
Meeting Library | Meeting Library
Meetinglibrary.asco.org 50h 1 tweets
Omid Hamid MD #ASCO20 Apparently Semaphorin 4D is the #Bouncer at the club not letting your TCells in. pepinemab (VX15/2503) puts you on the VIP list ! #PD1 #resistance 50h
Meeting Library | Meeting Library
Meetinglibrary.asco.org 50h 1 tweets
Omid Hamid MD #ASCO20 Dr. Hecht presents #TVEC intrahepatic tx with #PD1 We are aware of the poorer prognosis of patients with hepatic mets. Perhaps a beginning to overcoming this obstacle 50h
ASCO Meetings
Meetings.asco.org 17d 8 tweets
Danny Fund
Dannyfund.org 4d 1 tweets
Omid Hamid MD #MelanomaAwarenessMonth Fashion courtesy of and Danny Fund - Danny Federici Amazing man and story #donate #support 4d
Effect of various decontamination procedures on disposable N95 mask integrity and SARS-CoV-2 infectivity
medRxiv 4d 1 tweets
The COVID-19 pandemic has created a high demand on personal protective equipment, including disposable N95 masks. Given the need for mask reuse, we tested the feasibility of vaporized hydrogen peroxide (VHP), ultraviolet light (UV), and ethanol...
Omid Hamid MD SO #TasmanianDevil casually states "I Set up a BSL 2+ lab to grow SARS-CoV-2 so we could test different ways to decontaminate PPE" #finishCOVID #Fanboy #covid19 4d
ImmunoOncology
YouTube 5d 1 tweets
Omid Hamid MD Looking for a Patient Friendly video site with information on #immunotherapy #targetedtherapy #melanoma ? Try this one: 5d
Role of Circulating Tumor Cells/DNA & Liquid Biopsy in Melanoma - David Polsky
YouTube 5d 1 tweets
David Polsky MD,PhD Professor of Cutaneous Oncology at NYU discusses the role of Circulating Tumor DNA and Liquid Biopsy in Melanoma care in the Metastatic a...
Omid Hamid MD David Polsky MD,PhD Professor of Cutaneous Oncology discusses the role of Circulating Tumor DNA and Liquid Biopsy in #Melanoma care in the #Metastatic and #Adjuvant settings #MelanomaAwarenessMonth #immunotherapy 5d
Cancer cell therapies: the clinical trial landscape
Nature.com 5d 5 tweets
Discover the world’s best science and medicine | Nature.com
Providence coronavirus vaccine proposal centers on cancer-fighting technique
oregonlive 61d 3 tweets
The researchers decided to pivot to the pandemic.
1
Omid Hamid MD is a Tamanian Devil !! Making a difference in SO many ways thru to #finishCOVID #COVID19 #vaccine #FANBOY 5d
Meeting Library | Meeting Library
Meetinglibrary.asco.org 6d 1 tweets
1
Omid Hamid MD answering questions #ASCO20 In pts resistant to PD1, IPI+PD1 has higher RR, survival, similar high grade tox vs IPI alone. #ImmunoOnc 6d
SSO Virtual Tumor Boards Focus on Cancer Care Amid COVID-19 | Society of Surgical Oncology
Society of Surgical Oncology 9d 1 tweets
Check-out SSO’s new multidisciplinary virtual tumor boards that focus on treating specific cases during COVID-19. The following virtual tumor boards are upcoming and will be archived on [email protected] Breast Cancer Virtual Tumor Board, Thursday, May...
Announcement of the Passing of Val Guild, Founder & President of AIM - AIM at Melanoma Foundation
AIM at Melanoma Foundation 9d 3 tweets
2
Omid Hamid MD Mourning the loss of Valerie Guild #fighter #Leader #friend #mother We will carry on her fight 9d
Clinical Trials - Active Protocol Detail
Ccresources.ucdmc.ucdavis.edu 103d 1 tweets
Meeting Library | Meeting Library
Meetinglibrary.asco.org 9d 1 tweets
2
Omid Hamid MD #melanoma #ASCO20 favorable anti-tumor effect (FATE) post 2 doses IPI/Nivo first 2 doses of nivo + ipi appear to drive combo’s response efficacy/toxicity #Immunotherapy 9d
Meeting Library | Meeting Library
Meetinglibrary.asco.org 9d 1 tweets
Omid Hamid MD Ready for #ASCO20 #adjuvant therapy Updated Keynote 54 #pembrolizumab vs placebo 3-yr cumulative incidence distant metastasis first recurrence 22.3% (pembrolizumab group) vs 37.3% (placebo group) (HR 0.55, 95% CI 0.44-0.69). 9d